L-tosyl-histidine | 21013-92-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-tosyl-histidine
• 英文别名: 3-(1H-imidazol-4-yl)-2(S)-{[(4-methylphenyl)sulfonyl]amino}propanoic acid；N^α-(toluene-4-sulfonyl)-L-histidine；N^α-(Toluol-4-sulfonyl)-L-histidin；tosyl-L-histidine；(2S)-3-(1H-imidazol-5-yl)-2-[(4-methylphenyl)sulfonylamino]propanoic acid
• CAS: 21013-92-3
• 化学式: C₁₃H₁₅N₃O₄S
• 分子量: 309.346
• InChiKey: VZPHXKVSMQQSEI-LBPRGKRZSA-N

物化性质

• 沸点：
  618.9±65.0 °C(Predicted)
• 密度：
  1.428±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2935009090

反应信息

• 作为反应物：
  描述：

  4-羟基哌啶 、 氰基磷酸二乙酯 、 L-tosyl-histidine 在 三乙胺 作用下， 以 Boc-Nim 、 二氯甲烷 为溶剂， 生成 (S)-{2-(4-Hydroxy-piperidin-1-yl)-2-oxo-1-[1-(toluene-4-sulfonyl)-1H-imidazol-4-ylmethyl]-ethyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides

  摘要：

  公开号：

  EP1134213B1
• 作为产物：
  描述：

  2‐(toluene‐4‐sulfonylamino)‐3‐[1‐(toluene‐4‐sulfonyl)‐1H‐imidazol‐4‐yl]propionic acid methyl ester 在 sodium hydroxide 作用下， 生成 L-tosyl-histidine
  参考文献：
  名称：

  Helferich; Boeshagen, Chemische Berichte, 1959, vol. 92, p. 2813,2826

  摘要：

  DOI：

文献信息

• Novel amino acid derivatives possessing renin-inhibitory activities
  申请人：Japan Tobacco Inc.

  公开号：EP0396065A1

  公开（公告）日：1990-11-07

  An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.

  通用公式的氨基酸衍生物： 其中R1为 其中，R10为较低的烷基基团，R"为 （其中R111为较低的烷基基团，n为1至5的整数）或者可以被羟基或甲氧乙氧甲氧基取代的较低烷基基团，或者R'°和R"与相邻的氮原子 结合在一起； R12为氢原子，CnH2n+1-O-CO-（n如上定义）或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-（n和R12如上定义）和吡啶基取代的较低烷基基团； X为-CH2-、-O-或-NH-，Y为-O-或-NH-；其中 （其中Z为-0-、-S-、-S(O)-、-S(O)2-、-CH2-、-CH(OH)-， 或 a和b分别独立为1至4的整数，且a和b的总和不超过5）； R2为可以被较低烷基基团取代的芳基烷基基团； R3为氢原子或较低烷基基团； R4为较低烷基基团； A为羟基，B为氢原子，或者A和B与相邻的碳原子结合在一起，描述了一种药学上可接受的酸盐或其酯。本发明的化合物具有对肾素的抑制活性，并可用作降压药。
• Renin inhibitory peptides containing suleptanic acid or derivatives thereof
  申请人：THE UPJOHN COMPANY

  公开号：EP0355065A1

  公开（公告）日：1990-02-21

  The present invention provides novel renin-inhibiting peptides having a non-cleavable transition state insert corresponding to the 10,11- position of the renin substrate (angiotensinogen) and having a suleptanic acid moiety or derivatives thereof of the formula L₁ at the N-terminus of the peptide. Such inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin dependent hyperaldosterism, other renin depen­dent cardiovascular disorders and ocular disorders. Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁

  本发明提供了一种新型的抑制肾素的肽，其具有对应于肾素底物（血管紧张素原）的10,11位的不可切割过渡态插入物，并在肽的N-末端具有苏力帕尼酸基团或其衍生物的L₁式。这种抑制剂对于诊断和控制肾素依赖性高血压、充血性心力衰竭、肾素依赖性高醛固酮症、其他肾素依赖性心血管疾病和眼部疾病非常有用。Y₁0₃S-(CH₂)n-N(R₁)--(CH₂)q--      L₁
• Renin inhibitor peptide compounds, a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04963530A1

  公开（公告）日：1990-10-16

  A compound of the formula: ##STR1## wherein R.sup.1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R.sup.2 is hydrogen or lower alkyl, or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R.sup.3 is hydrogen or lower alkyl, and R.sup.4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same.

  化合物的式子为：##STR1## 其中R.sup.1是芳基，可选地被卤素和卤代（低）烷基取代；低碳基或环（低）烷基；R.sup.2是氢或低碳基，或R.sup.1和R.sup.2与附着的氮原子一起形成杂环基，可选地被选自低碳基和酯化羧基的取代基取代，R.sup.3是氢或低碳基，R.sup.4是低碳基，以及其药学上可接受的盐，其制备方法和包含其的药物组成。
• Amino acid derivatives, processes for the preparation thereof and
  申请人：Ujisawa Pharmaceutical Co., Ltd.

  公开号：US05223489A1

  公开（公告）日：1993-06-29

  A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted aryl; or amino optionally substituted; and R.sup.2 is hydrogen or lower alkyl; or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted; R.sup.3 is hydrogen or lower alkyl; and R.sup.4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same

  一种化合物的公式：##STR1##其中R.sup.1是低碳基可选择取代芳基; 或氨基可选择取代; R.sup.2是氢或低碳基; 或R.sup.1和R.sup.2与所连接的氮原子一起形成可选择取代的杂环基团; R.sup.3是氢或低碳基; R.sup.4是低碳基; 以及其药学上可接受的盐，其制备方法和包含该化合物的药物组成物。
• Amino acid derivatives, a process for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05491132A1

  公开（公告）日：1996-02-13

  This invention relates to new amino acid derivatives and pharmaceutically acceptable salts thereof, wherein the amino acid derivatives are useful in the treatment and/or prevention of hypertension, heart failure, renal diseases or glaucoma.

  本发明涉及新的氨基酸衍生物及其药学上可接受的盐，其中所述氨基酸衍生物在治疗和/或预防高血压、心力衰竭、肾脏疾病或青光眼方面有用。